RxDoctor Payments Data

Natalya Malakova

Optometrist · Forest Hills, NYNPI 1497795983

Payments from drug & device makers

$592in general payments, 2019–2025

Across 9 payments — averaging $65.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$393
  • AbbVie$118
  • Tarsus Pharmaceuticals, Inc.$45
  • Carl Zeiss Meditec AG$19
  • Carl Zeiss Meditec, Inc.$17

What the payments were for

  • Food & beverage$55694%
  • Gifts$376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 50th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$229,433
Medicare patients
315
Services billed
3,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine680$421,593
XiidraLifitegrast117$75,725
Cyclosporine243$73,541
MieboPerfluorohexyloctane/Pf76$55,405
XdemvyLotilaner26$47,686
ZerviateCetirizine Hcl86$35,832
LumiganBimatoprost127$35,159
ZyletTobramycin/Lotepred Etab31$11,481
VyzultaLatanoprostene Bunod30$11,331
CombiganBrimonidine Tartrate/Timolol25$8,744
LotemaxLoteprednol Etabonate17$5,673
TobradexTobramycin/Dexamethasone21$5,466
Alphagan PBrimonidine Tartrate20$5,174
Brimonidine Tartrate46$4,225
Tobradex StTobramycin/Dexamethasone17$3,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$118$470,670852 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$393$142,461223 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$45$47,68626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,743 optometrist providers in New York.

Other optometrist in Forest Hills

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →